-
11.发明申请EX VIVO THERAPEUTICS SCREENING OF LIVING BONE MARROW CELLS FOR MULTIPLE MYELOMA 审中-公开用于多发性骨髓瘤的生物骨髓细胞的筛查治疗公开(公告)号：US20110207627A1
公开(公告)日：2011-08-25
申请号：US13057978
申请日：2009-08-12
CPC分类号： G01N33/56972 , G01N33/5011 , G01N2333/70596 , G01N2510/00 , G01N2800/52
摘要： Methods of selecting a treatment for a patient with multiple myeloma are provided. Prior to commencing a treatment regime, bone marrow aspirates are isolated from a patient and incubated with one or more candidate therapeutics. The methods identify the therapy or combination of therapies most likely to yield the best results for a particular individual. In addition to improving clinical outcome, such theranostic evaluations dramatically reduce health care costs, by avoiding ineffective therapies. Screening assays for identifying treatments for multiple myeloma also are provided.
摘要翻译： 提供了选择多发性骨髓瘤患者的治疗方法。 在开始治疗方案之前，从患者中分离骨髓抽吸物并与一种或多种候选治疗剂一起温育。 该方法确定最有可能为特定个体产生最佳结果的治疗或疗法组合。 除了改善临床结果之外，这种诊断性评估通过避免无效疗法，大大降低了医疗保健成本。 还提供了用于鉴定多发性骨髓瘤治疗的筛选试验。
-
公开(公告)号：US20100203549A1
公开(公告)日：2010-08-12
申请号：US12676257
申请日：2008-09-05
CPC分类号： G01N33/96 , G01N33/5005
摘要： This invention relates, e.g., to a set of calibrants for determining the amount in a sample of an analyte (e.g., a protein, such as a protein that has been post-translationally modified), comprising a plurality of calibrants, which contain a range of amounts (e.g., defined amounts and/or serial dilutions) of the analyte, spanning the expected amount of the analyte in the sample. In each of the calibrants, a defined amount of the analyte is present in the same suitable, biological diluent (e.g., a cell or tissue lysate, or a bodily fluid). In one embodiment of the invention, the diluent reflects the same or a similar biological milieu (proteins, lipids, serum proteins, serum matrix proteins, etc.) as that in the sample in which the analyte to be measured is present. In embodiments of the invention, a single calibrant (e.g., a cell lysate) may comprise as many as hundreds of analytes, and can be used for the quantification of those hundreds of analytes in a sample. Methods are described for performing an assay (e.g. RPMA analysis), in which the calibrants of a set of calibrants of the invention are immobilized on each of the surfaces to which samples to be analyzed are immobilized, thereby providing an internal calibration curve for quantifying an RPMA assay.
摘要翻译： 本发明涉及例如用于确定分析物样品中的量（例如蛋白质，例如经翻译后修饰的蛋白质）的一组校准剂，其包含多个校准物，其包含范围 的分析物的量（例如，定义的量和/或连续稀释度），跨越样品中分析物的预期量。 在每个校准中，一定量的分析物存在于相同的合适的生物稀释剂（例如，细胞或组织裂解液或体液）中。 在本发明的一个实施方案中，稀释剂反映与待测分析物存在的样品中相同或相似的生物环境（蛋白质，脂质，血清蛋白，血清基质蛋白等）。 在本发明的实施方案中，单个校准物（例如，细胞裂解物）可以包含多达数百种分析物，并且可以用于量化样品中数百种分析物。 描述了用于进行测定（例如RPMA分析）的方法，其中将本发明的一组校准物的校准物固定在固定有待分析样品的每个表面上，从而提供内部校准曲线，用于量化 RPMA测定。
-
13.发明申请公开(公告)号：US20090275546A1
公开(公告)日：2009-11-05
申请号：US12386002
申请日：2009-04-10
IPC分类号： A61K31/395 , C40B30/06 , C12N5/02
CPC分类号： G01N33/57419 , A61K31/00 , A61K31/395 , G01N33/57496 , G01N2333/485 , G01N2333/71 , G01N2800/52
摘要： Provided are methods of identifying a metabolic target in a cancer stem cell that include using a microarray to identify intracellular signaling networks within a population of cancer stem cells that respond to a growth factor for the stem cell. Also provided are methods of determining a personalized therapeutic regime that include receiving metabolic information relating to a cancer stem cell in a patient, determining the patient's personal criteria relevant to the therapeutic regime, and combining the metabolic and personal criteria. Also provided are a diagnostic test for establishing a personalized therapeutic regime for a colon cancer patient and methods of reducing colon cancer stem cells/treating colon cancer.
摘要翻译： 提供了确定癌症干细胞中的代谢靶标的方法，其包括使用微阵列来鉴定响应干细胞生长因子的癌干细胞群体内的细胞内信号传导网络。 还提供了确定个体化治疗方案的方法，其包括接收与患者中的癌干细胞相关的代谢信息，确定患者与治疗方案相关的个人标准，以及组合代谢和个人标准。 还提供了建立结肠癌患者的个性化治疗方案的诊断测试和减少结肠癌干细胞/治疗结肠癌的方法。
-
14.发明申请SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR MANIPULATING THERANOSTIC ASSAYS 审中-公开用于操纵治疗测定的系统，方法和计算机程序产品公开(公告)号：US20080243394A1
公开(公告)日：2008-10-02
申请号：US12057163
申请日：2008-03-27
IPC分类号： G01N33/569 , C12Q1/02 , G06F19/00
摘要： A theranostics technique for describing signaling pathway activity within a cellular or tissue sample may include analyzing a cellular sample to obtain sample quantitative values for a series of target protein modification levels reflected in a set of a plurality of protein biomarkers in the sample. The sample quantitative values may be compared to reference quantitative values for the same series of protein modification levels. The reference quantitative values may be statistically processed from a plurality of comparable samples. The sample quantitative values may be displayed in relation to the reference quantitative values in a way that may suggest a specific course of treatment.
摘要翻译： 用于描述细胞或组织样品中的信号传导途径活性的治疗技术可包括分析细胞样品以获得反映在样品中的多组蛋白质生物标志物的一组中的一系列靶蛋白修饰水平的样品定量值。 样品定量值可以与相同系列蛋白质修饰水平的参考定量值进行比较。 参考定量值可以从多个可比样品进行统计学处理。 样品定量值可以以可能表明具体治疗过程的方式相对于参考定量值显示。
-
公开(公告)号：US07226731B1
公开(公告)日：2007-06-05
申请号：US09743825
申请日：1999-07-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： A novel gene, PB39, that is up-regulated, or over-expressed, in prostate cancer has been identified. The gene has been identified by means of its cDNA obtained by reverse transcription of the corresponding mRNA. Microdissection of prostate glands that had been surgically removed from prostate cancer patients revealed a novel up-regulated transcript in an aggressive prostate carcinoma. Differential analysis for the presence of this gene was carried out from the same glands by comparing transcription in microdissected normal prostatic epithelium versus that in microdissected invasive tumor. The transcript was over-expressed in 5 of 10 prostate carcinomas examined. A variant transcript was over-expressed in 4 of 4 prostate carcinomas, and was found in 1 of 4 normal samples. The invention provides a purified and isolated nucleic acid that includes the sequence of PB39 or its complement, the sequence of a variant of PB39 or its complement, and a primer or probe, that includes a sequence that is a fragment of these sequences. Additionally, the polypeptide encoded by these genes, an antibody to the polypeptide, and methods of detection of PB39 or its gene product are provided.
摘要翻译： 已经鉴定出在前列腺癌中上调或过度表达的新基因PB39。 该基因已通过其相应mRNA的逆转录获得的cDNA鉴定。 从前列腺癌患者手术切除的前列腺的显微解剖显示在侵袭性前列腺癌中有一种新的上调的转录物。 通过比较显微解剖正常前列腺上皮中的转录与微切割侵袭性肿瘤中的转录，从相同腺体进行差异分析。 在检查的10个前列腺癌中的5个中，转录物过表达。 在4个前列腺癌中的4个中，变体转录物过表达，并且在4个正常样品中的1个中发现。 本发明提供了纯化和分离的核酸，其包括PB39或其互补序列，PB39或其互补序列变体的序列，以及引物或探针，其包括作为这些序列的片段的序列。 另外，提供了由这些基因编码的多肽，多肽的抗体，以及检测PB39或其基因产物的方法。
-
16.发明授权Rapid fluorescent labeling of tissue for microdissection using fluorescent specific binding agents 失效使用荧光特异性结合剂快速荧光标记用于显微切割的组织公开(公告)号：US06790636B1
公开(公告)日：2004-09-14
申请号：US09881446
申请日：2001-06-13
IPC分类号： G01N3348
CPC分类号： G01N33/533 , G01N1/2813 , G01N2001/284
摘要： Methods are disclosed for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents are also included. A laser capture microdissection apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed.
摘要翻译： 公开了用于生物组织样品的快速和特异性荧光染色的方法，其基本上保留生物分子例如mRNA。 还包括基于识别和切除用荧光特异性结合剂标记的细胞或组织结构来显微解剖组织以获得纯细胞群或组织结构的方法。 还公开了用于在快速免疫荧光染色之后鉴定和分离细胞和组织结构的激光捕获显微切割装置。
-
公开(公告)号：US06274134B1
公开(公告)日：2001-08-14
申请号：US08083945
申请日：1993-06-25
IPC分类号： A61K4500
CPC分类号： C07K16/2803 , A61K38/00 , C07K14/70503 , G01N33/56977 , G01N33/56988 , G01N33/6893
摘要： The present invention relates, in general, to AAMP-1, and to a peptide derived from the amino-terminal region of AAMP, P189. In particular, the present invention relates to a DNA segment encoding AAMP-1, P189 or fragments thereof; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a AAMP-1, and P189 polypeptide or fragments thereof; antibodies specific to AAMP-1; and a method of measuring the amount of AAMP-1 in a sample. The present invention further relates to methods of using AAMP, P189 or fragments thereof in promoting cell-cell or cell-substrate adhesion, wound healing in patients, prosthetic acceptance, concentrating heparin in tissues, and inhibiting metastases and invasion of malignant cells.
摘要翻译： 本发明一般涉及AAMP-1，以及衍生自AAMP的氨基末端区域的肽，P189。 特别地，本发明涉及编码AAMP-1，P189或其片段的DNA片段; 由所述DNA片段编码的多肽; 含有DNA片段的重组DNA分子; 含有重组DNA分子的细胞; 生产AAMP-1的方法和P189多肽或其片段; AAMP-1特异性抗体; 以及测定样品中AAMP-1的量的方法。 本发明还涉及使用AAMP，P189或其片段促进细胞或细胞 - 底物粘附，患者中的伤口愈合，假体接受，组织中浓缩肝素以及抑制恶性细胞的转移和侵袭的方法。
-
公开(公告)号：US5880129A
公开(公告)日：1999-03-09
申请号：US906542
申请日：1997-08-05
IPC分类号： A61K31/12 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4192 , C07D233/90 , C07D249/04 , A61K31/495 , A61K31/505 , C07D239/26 , C07D241/10
CPC分类号： A61K31/12 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4192 , C07D233/90 , C07D249/04
摘要： A discovery underlying this invention is the concordance between particular cellular signaling mechanisms and cancer cell growth and metastasis. It has now been discovered that certain compounds inhibit the signal transduction required for the maintenance and driving of the malignant process. These compounds are also effective for the in vivo treatment of solid tumors and related disease states. This invention provides a method for the use of these compounds to inhibit the invasion and metastasis of malignant solid tumors in mammals. This invention further provides a method for using related compounds to treat diseases involving aberrant signal transduction pathways. Some of the compounds used in the methods of the present invention are novel and constitute another aspect of this invention.
摘要翻译： 本发明的发现是特定细胞信号传导机制与癌细胞生长和转移之间的一致性。 现在已经发现某些化合物抑制维持和驱动恶性过程所需的信号转导。 这些化合物对于实体瘤和相关疾病状态的体内治疗也是有效的。 本发明提供了一种使用这些化合物抑制哺乳动物恶性实体瘤侵袭和转移的方法。 本发明还提供了使用相关化合物治疗涉及异常信号转导途径的疾病的方法。 在本发明的方法中使用的一些化合物是新的，构成本发明的另一方面。
-
19.发明授权Methods and compositions for increasing the sensitivity of a cell to a DNA damaging agent 失效提高细胞对DNA损伤剂敏感性的方法和组合物
公开(公告)号：US5770386A
公开(公告)日：1998-06-23
申请号：US886368
申请日：1992-05-20
IPC分类号： G01N33/577 , A61K31/70 , A61K48/00 , A61P35/00 , A61P43/00 , C12N5/10 , C12N9/12 , C12N15/09 , C12P21/02 , C12Q1/02 , G01N33/574 , C12Q1/00 , G01N33/573
CPC分类号： C12N9/12 , Y10S436/813
摘要： The invention provides a method of increasing the sensitivity of a cell to a DNA damaging agent comprising increasing the amount of an NM23 in the cell. The method is especially useful for increasing the sensitivity of tumor cells to chemotherapy and radiation.
摘要翻译： 本发明提供了增加细胞对DNA损伤剂的敏感性的方法，包括增加细胞中NM23的量。 该方法对增加肿瘤细胞对化学疗法和放射线的敏感性尤其有用。
-
20.发明授权Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs 失效使用信号转导抑制剂与紫杉醇和其他紫杉烷类似物的联合治疗
公开(公告)号：US5565478A
公开(公告)日：1996-10-15
申请号：US212612
申请日：1994-03-14
申请人： Elise C. Kohn , Eddie Reed , Lance A. Liotta
发明人： Elise C. Kohn , Eddie Reed , Lance A. Liotta
IPC分类号： A61K31/40 , A61K31/415 , A61K31/41 , A61K31/335
CPC分类号： A61K31/40 , A61K31/415
摘要： The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of formula I defined herein in combination with paclitaxel or other modified taxane analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.
摘要翻译： 本发明提供了在受试者中治疗癌症的组合物和方法，其中本文定义的式I化合物与紫杉醇或其他修饰的紫杉烷类似物相结合，提供比单独化合物实现的效果更强的抗癌作用。
-
-
-
-
-
-
-
-
-
搜索结果
92 条记录 (耗时 0.053 秒)
